GlassScriptPhysician profile
Katy Farber Williams
NPI 1922360882
$2,575.19
in general payments reported to CMS, 2019-2025
23 companies · $135 in 2025
The $135 reported for 2025 was less than what a typical Obesity Medicine (Family Medicine) provider received nationally (typical 2025 total: $183).
See the full distribution for Obesity Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $954 · 2020: $131 · 2021: $118 · 2022: $358 · 2023: $751 · 2024: $128 · 2025: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $899 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $898.65 |
| Education | $114.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $703.72 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $304.47 | 2019-2023 | Mounjaro, Jardiance |
| Abbvie INC. | $275.56 | 2021-2023 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $200.99 | 2019-2023 | |
| Vivus LLC | $198.90 | 2024-2025 | Qsymia |
| Takeda Pharmaceuticals U.S.A., INC. | $106.14 | 2019-2022 | |
| Amgen INC. | $102.75 | 2019-2023 | Otezla |
| Glaxosmithkline, LLC. | $97.50 | 2019-2023 | Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $91.68 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.01 | 2022-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $66.34 | 2019-2022 | |
| Allergan, INC. | $65.60 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $53.16 | 2022 | |
| Astellas Pharma US INC | $52.62 | 2019-2023 | Veozah |
| Currax Pharmaceuticals LLC | $50.00 | 2023 | Nexletol |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $32.18 | 2019 | |
| Abbott Laboratories | $16.73 | 2024 | Freestyle Libre 3 |
| Shire North American Group INC | $15.99 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $15.69 | 2023 | Abilify Maintena, Rexulti |
| Collegium Pharmaceutical, INC. | $15.58 | 2019 | |
| Dexcom, INC. | $14.60 | 2025 | Dexcom G6 Transmitter |
| Lundbeck LLC | $13.59 | 2023 | Rexulti |
| Exact Sciences Corporation | $13.39 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katy Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.